



CLAIMS

1. A compound having Formula I:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

B is



R¹ is -N(H)R³;

Q¹ is =CH- and Q² is -N=; or

Q¹ is =N- and Q² is -CH=; or

Q¹ is =N- and Q² is -N=;

R³ is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;

X is selected from the group consisting of -C(=O)N(R^{2a})-, -CH₂N(R^{2b})-, -CH₂O-, -N(R^{2c})-, -O-, and -CH₂;

wherein the nitrogen atom of -C(=O)N(R^{2a})- and -CH₂N(R^{2b})- is attached to L, and the oxygen atom of -CH₂O- is attached to L;

L is selected from the group consisting of alkylene, heteroalkylene, and -(CH₂)_m-W-(CH₂)_n;

W is selected from the group consisting of optionally substituted phenylene, optionally substituted 5-membered heteroarylene, and optionally substituted 6-membered heteroarylene;

m is 0, 1, 2, 3, 4, 5, 6, or 7;

n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

Y is selected from the group consisting of -C≡C-, -CH₂-, -O-, -N(R^{2d})-, -C(=O)N(R^{2e})-, -N(R^{2f})C(=O)CH₂O-, and -N(R^{2g})C(=O)CH₂N(R^{2h})-; or

Y is absent;

wherein the carboxamide nitrogen atom of $-N(R^{2f})C(=O)CH_2O-$ and $-N(R^{2g})C(=O)CH_2N(R^{2h})-$, and the carbon atom of $-C(=O)N(R^{2e})-$ is attached to L;

R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , R^{2f} , R^{2g} , and R^{2h} are each independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

Z is selected from the group consisting of $-CH_2$ and $-C(=O)-$; and

R^5 is selected from the group consisting of hydrogen and fluoro,

with the proviso that Y is absent when B is B-2.

2. The compound of any one of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein L is C_{1-12} alkylene.

3. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH_2(CH_2)_2CH_2-$, $-CH_2(CH_2)_3CH_2-$, $-CH_2(CH_2)_4CH_2-$, $-CH_2(CH_2)_5CH_2-$, and $-CH_2(CH_2)_6CH_2-$.

4. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:

L is selected from the group consisting of $-(CH_2)_oO-(CH_2CH_2O)_p-(CH_2)_q-$ and $-(CH_2)_rO-(CH_2)_sO(CH_2)_t-$;

o is 2 or 3;

p is 0, 1, 2, 3, 4, 5, 6, or 7;

q is 2 or 3;

r is 2, 3, or 4;

s is 3, 4, or 5; and

t is 2 or 3.

5. The compound of claim 4, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from the group consisting of

$-CH_2CH_2OCH_2CH_2-$,


$-CH_2CH_2O(CH_2CH_2O)_2CH_2CH_2-$,

$-CH_2CH_2O(CH_2CH_2O)_3CH_2CH_2-$,

$-CH_2CH_2O(CH_2CH_2O)_4CH_2CH_2-$,

-CH₂CH₂O(CH₂CH₂O)₆CH₂CH₂-,
 -CH₂CH₂O(CH₂CH₂O)₆CH₂CH₂-,
 -CH₂CH₂CH₂OCH₂CH₂OCH₂CH₂CH₂-,
 -CH₂CH₂CH₂O(CH₂CH₂O)₂CH₂CH₂CH₂-, and
 -CH₂CH₂CH₂O(CH₂)₄OCH₂CH₂CH₂-.

6. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **IV**:



wherein:


B is B-1;

Y is selected from the group consisting of -C≡C-, -CH₂-, and -N(H)-;

m is 1, 2, or 3; and

n is 0, 1, 2, 3, or 4.

7. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **V**:



wherein:


B is B-1;

Y is selected from the group consisting of -C≡C-, -CH₂-, and -N(H)-;

m is 0, 1, or 2; and

n is 0, 1, 2, or 3.

8. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **VI**:



wherein:

B is B-1;


Y is selected from the group consisting of $-C\equiv C-$, $-CH_2-$, and $-N(H)-$;

R^6 is selected from the group consisting of hydrogen and methyl;

m is 0, 1, 2, or 3; and

n is 1, 2, or 3.

9. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **VII**:



wherein:

B is B-1;


Y is selected from the group consisting of $-C\equiv C-$, $-CH_2-$, and $-N(H)-$;

R^6 is selected from the group consisting of hydrogen and methyl;

m is 0, 1, 2, or 3; and

n is 1, 2, or 3.

10. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **VIII**:



wherein:






B is B-1;






n is 0, 1, 2, 3, or 4.






IX.






n is 0, 1, 2, or 3.


Chemical structures of two compounds, 1 and 2, separated by a semicolon. Both compounds are complex organic molecules featuring a central indazole core. The left side of the core is substituted with a 4-methoxy-2-methyl-1,2,4-oxadiazole group. The right side is substituted with a 1-ethyl-4-(cyclopropyl)-1H-1,2,4-triazol-5-yl group. The indazole core is linked via a carbonyl group to a long chain. In compound 1, this chain is a 4-((4-((2-oxo-2,3-dihydro-1H-benzofuro[3,2-b]pyridin-6-yl)oxy)acetyl)amino)butanamide. In compound 2, the chain is a 4-((4-((2-oxo-2,3-dihydro-1H-benzofuro[3,2-b]pyridin-6-yl)oxy)acetyl)amino)oxybutanamide. Both structures end with a semicolon.


















































;




;







;












;




;










13. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

14. Use of a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a patient, wherein the patient has cancer, a chronic autoimmune disorder, an inflammatory condition, a proliferative disorder, sepsis, or a viral infection.

15. A kit comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a patient having cancer.

16. A compound having Formula **XIV**:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is $-N(H)R^3$;

Q^1 is $=CH-$ and Q^2 is $-N=$; or

Q^1 is $=N-$ and Q^2 is $-CH=$; or

Q^1 is $=N-$ and Q^2 is $-N=$;

R^3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;

R^{7a} is selected from the group consisting of chloro and $-OR^{7b}$; and

R^{7b} is selected from the group consisting of hydrogen and C_{1-4} alkyl.

17. Use of a compound of claim 2, or a pharmaceutically acceptable salt, or solvate thereof, in the manufacture of a medicament for reducing BET bromodomain protein within a cell of a patient in need.